Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
NCT01393106Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2011
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idelalisib in Hodgkin lymphoma (HL), sponsored by Gilead Sciences. Primary endpoint: Overall Response Rate. Started Sep 2011; status: completed.
02
Drugs
idelalisib
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01393106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01393106.